New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
The tumor necrosis factor-а inhibitor etanercept (ETC) is one of the most popular members of the group of biologic disease-modifying antirheumatic drugs used for treatment of immune-mediated inflammatory rheumatic diseases (IRD). According to a series of double-blind randomized controlled trials (RC...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1377 |